We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-12.68%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.45B
AUM Growth
-$497M
Cap. Flow
+$144M
Cap. Flow %
5.89%
Top 10 Hldgs %
73.47%
Holding
55
New
2
Increased
12
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$62.7M
2
KURA icon
Kura Oncology
KURA
+$40.4M
3
AXSM icon
Axsome Therapeutics
AXSM
+$34.4M
4
RVMD icon
Revolution Medicines
RVMD
+$32.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$28.3M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$35.3M
2
ETNB
89bio
ETNB
+$33.9M
3
GHRS icon
GH Research
GHRS
+$17.6M
4
XOMA
Xoma
XOMA
+$15.7M
5
ENGN icon
enGene Therapeutics
ENGN
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.59B
$772M 31.45%
19,751,284
– –
AXSM icon
2
Axsome Therapeutics
AXSM
$11.5B
$197M 8.03%
1,690,221
+302,157
+22% +$34.4M
RVMD icon
3
Revolution Medicines
RVMD
$39.9B
$176M 7.18%
4,982,384
+801,205
+19% +$32.5M
KYMR icon
4
Kymera Therapeutics
KYMR
$8.6B
$141M 5.76%
5,161,801
– –
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.66B
$126M 5.13%
2,796,513
– –
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.7B
$125M 5.08%
2,575,015
+675,000
+36% +$28.3M
GHRS icon
7
GH Research
GHRS
$1.95B
$97.4M 3.97%
8,827,712
-1,572,446
-15% -$17.6M
XOMA
8
DELISTED
Xoma
XOMA
$59.5M 2.42%
2,983,026
-650,717
-18% -$15.7M
IONS icon
9
Ionis Pharmaceuticals
IONS
$8.61B
$57.7M 2.35%
+1,913,385
New +$62.7M
ZYME icon
10
Zymeworks
ZYME
$1.63B
$51.3M 2.09%
4,308,935
– –
KURA icon
11
Kura Oncology
KURA
$805M
$51.2M 2.09%
7,754,129
+5,186,660
+202% +$40.4M
CGEM icon
12
Cullinan Oncology
CGEM
$1.03B
$43.5M 1.77%
5,750,683
– –
ACIU icon
13
AC Immune
ACIU
$226M
$37.1M 1.51%
19,822,436
+300,000
+2% +$756K
TYRA icon
14
Tyra Biosciences
TYRA
$1.91B
$36.7M 1.5%
3,944,194
– –
LKFT
15
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
$36.5M 1.49%
1,454,422
-115,000
-7% -$2.91M
CELC icon
16
Celcuity
CELC
$4.25B
$35M 1.43%
3,466,000
– –
VERV
17
DELISTED
Verve Therapeutics
VERV
$31.6M 1.29%
6,904,050
– –
GPCR icon
18
Structure Therapeutics
GPCR
$3.38B
$30.7M 1.25%
1,771,417
– –
XNCR icon
19
Xencor
XNCR
$1.53B
$29.2M 1.19%
2,740,141
+451,381
+20% +$7.46M
GLUE icon
20
Monte Rosa Therapeutics
GLUE
$1.33B
$26.3M 1.07%
5,660,132
+2,895,661
+105% +$17.8M
SEPN
21
Septerna Inc
SEPN
$1.56B
$25.5M 1.04%
4,396,124
+1,944,100
+79% +$22.2M
ELDN icon
22
Eledon Pharmaceuticals
ELDN
$257M
$21.3M 0.87%
6,293,282
– –
CDTX
23
DELISTED
Cidara Therapeutics
CDTX
$19.9M 0.81%
924,642
-168,154
-15% -$3.74M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1.02B
$19.9M 0.81%
5,295,893
-420,000
-7% -$2.11M
PVLA
25
Palvella Therapeutics
PVLA
$2.05B
$19.5M 0.79%
696,555
– –
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2025 Portfolio in Review

As of Q1 2025, BVF Inc held 55 positions worth $2.45B, down 17% from $2.95B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BVF Inc deployed $144M of net new capital in Q1 2025, opening 2 new positions and adding to 12 existing holdings. Its largest new stake was Ionis Pharmaceuticals: 1,913,385 shares worth $57.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was GH Research, an estimated $17.6M trimmed.

  • BVF Inc's largest Q1 2025 buy was Ionis Pharmaceuticals: 1,913,385 shares worth $57.7M.
  • BVF Inc added most to Kura Oncology in Q1 2025, an estimated $40.4M increase.
  • BVF Inc's biggest Q1 2025 reduction was GH Research, cutting an estimated $17.6M.
  • BVF Inc fully exited Agios Pharmaceuticals in Q1 2025, selling an estimated $35.3M.
  • BVF Inc's ten largest holdings make up 73% of its $2.45B portfolio in Q1 2025.
  • BVF Inc opened 2 new positions and closed 4 in Q1 2025.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.45B.

Based on BVF Inc's 13F filing for Q1 2025, filed 15 May 2025.